Literature DB >> 33614028

The role of faecal microbiota transplantation: looking beyond Clostridioides difficile infection.

Simon D Goldenberg1, Blair Merrick2.   

Abstract

Faecal microbiota transplantation (FMT) is the transfer of screened and minimally processed faecal material from a 'healthy' donor to 'diseased' recipient. It has an established role, and is recommended as a therapeutic strategy, in the management of recurrent Clostridioides difficile infection (CDI). Recognition that gut dysbiosis is associated with, and may contribute to, numerous disease states has led to interest in exploiting FMT to 'correct' this microbial imbalance. Conditions for which it is proposed to be beneficial include inflammatory bowel disease, irritable bowel syndrome, liver disease and hepatic encephalopathy, neuropsychiatric conditions such as depression and anxiety, systemic inflammatory states like sepsis, and even coronavirus disease 2019. To understand what role, if any, FMT may play in the management of these conditions, it is important to consider the potential risks and benefits of the therapy. Regardless, there are several barriers to its more widespread adoption, which include incompletely understood mechanism of action (especially outside of CDI), inability to standardise treatment, disagreement on its active ingredients and how it should be regulated, and lack of long-term outcome and safety data. Whilst the transfer of faecal material from one individual to another to treat ailments or improve health has a history dating back thousands of years, there are fewer than 10 randomised controlled trials supporting its use. Moving forward, it will be imperative to gather as much data from FMT donors and recipients over as long a timeframe as possible, and for trials to be conducted with rigorous methodology, including appropriate control groups, in order to best understand the utility of FMT for indications beyond CDI. This review discusses the history of FMT, its appreciable mechanisms of action with reference to CDI, indications for FMT with an emerging evidence base above and beyond CDI, and future perspectives on the field.
© The Author(s), 2021.

Entities:  

Keywords:  clostridioides difficile infection (CDI); dysbiosis; faecal microbiota transplantation (FMT); inflammatory bowel disease (IBD); irritable bowel syndrome (IBS); liver disease

Year:  2021        PMID: 33614028      PMCID: PMC7841662          DOI: 10.1177/2049936120981526

Source DB:  PubMed          Journal:  Ther Adv Infect Dis        ISSN: 2049-9361


  10 in total

1.  Case Report: Oral Fecal Microbiota Transplantation in a Dog Suffering From Relapsing Chronic Diarrhea-Clinical Outcome and Follow-Up.

Authors:  Matteo Cerquetella; Andrea Marchegiani; Giacomo Rossi; Massimo Trabalza-Marinucci; Fabrizio Passamonti; Marco Isidori; Fabrizio Rueca
Journal:  Front Vet Sci       Date:  2022-07-04

2.  Global Research Trends in Irritable Bowel Syndrome: A Bibliometric and Visualized Study.

Authors:  Tai Zhang; Xiangxue Ma; Wende Tian; Jiaqi Zhang; Yuchen Wei; Beihua Zhang; Fengyun Wang; Xudong Tang
Journal:  Front Med (Lausanne)       Date:  2022-06-27

3.  Gut microbiome and neurosurgery: Implications for treatment.

Authors:  Jonathan Willman; Matthew Willman; Ramya Reddy; Anna Fusco; Sai Sriram; Yusuf Mehkri; Jude Charles; Joel Goeckeritz; Brandon Lucke-Wold
Journal:  Clin Transl Discov       Date:  2022-10-10

Review 4.  Gut bless you: The microbiota-gut-brain axis in irritable bowel syndrome.

Authors:  Eline Margrete Randulff Hillestad; Aina van der Meeren; Bharat Halandur Nagaraja; Ben René Bjørsvik; Noman Haleem; Alfonso Benitez-Paez; Yolanda Sanz; Trygve Hausken; Gülen Arslan Lied; Arvid Lundervold; Birgitte Berentsen
Journal:  World J Gastroenterol       Date:  2022-01-28       Impact factor: 5.742

5.  Recurrent Campylobacter jejuni Infection in an Immunodeficient Patient Treated with Repeated Faecal Microbiota Transplant (FMT)-A Case Report.

Authors:  Blair Merrick; Aravind Gokul Tamilarasan; Raphael Luber; Patrick F K Yong; Kuldeep Cheent; Peter M Irving; Manjula Meda; Simon D Goldenberg
Journal:  Infect Dis Rep       Date:  2022-01-12

Review 6.  The emerging potential of microbiome transplantation on human health interventions.

Authors:  Howard Junca; Dietmar H Pieper; Eva Medina
Journal:  Comput Struct Biotechnol J       Date:  2022-01-19       Impact factor: 7.271

7.  Global research on Clostridium difficile-associated diarrhoea: A visualized study.

Authors:  Sa'ed H Zyoud
Journal:  World J Gastroenterol       Date:  2022-07-28       Impact factor: 5.374

8.  Effect of fecal microbiota transplantation on the TGF-β1/Smad signaling pathway in rats with TNBS-induced colitis.

Authors:  Jinlang Qiu; Caixian Wu; Qianyu Gao; Sheng Li; Yuhua Li
Journal:  Ann Transl Med       Date:  2022-08

9.  Efficacy and safety of fecal microbiota transplant in irritable bowel syndrome: An update based on meta-analysis of randomized control trials.

Authors:  Yomna Ali Abdelghafar; Yossef Hassan AbdelQadir; Karam R Motawea; Sara Amr Nasr; Hoda Aly Mohamed Omran; Mohamed Mohamed Belal; Mohamed Mahdy Elhashash; Ahmed Alaa AbdelAzim; Jaffer Shah
Journal:  Health Sci Rep       Date:  2022-09-12

Review 10.  Targeting the gut microbiome in the management of sepsis-associated encephalopathy.

Authors:  Brooke Barlow; Sameer Ponnaluri; Ashley Barlow; William Roth
Journal:  Front Neurol       Date:  2022-09-29       Impact factor: 4.086

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.